본문 바로가기
KERD
논문KCI 등재

한국형 양극성 장애 약물치료 알고리듬 2022: 소아/청소년

Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents

전덕인|정명훈|우영섭|추일한|박성용|서정석|김원|정종현|이정구|윤보현|김문두|심세훈|손인기|박원명|양찬모
대한신경정신의학회 (Korean Neuropsychiatric Association)|2022.08|신경정신의학 (JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION)|제61권 제3호|pp. 224-236|DOI https://doi.org/10.4306/jknpa.2022.61.3.224

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Bipolar disorderPharmacotherapyChildren and adolescentsKMAP-BP 2022.
주제분류정신과학

초록

Objectives The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents. Methods We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey. Results The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatme f choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, andmonotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategiesfor depressive episodes in adolescents were a combination of MS and an AAP, monotherapywith MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for thedepressive episodes in adolescents at high risk for bipolar disorder were a combination of MSand AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, andrisperidone were selected as first-line medications for the treatment of depressive episodes inadolescents with bipolar disorder. Conclusion It is expected that the present KMAP-BP 2022: children and adolescents will givethe direction and be usefully applied by clinicians to treat children and adolescents with bipolardisorders.

Abstract

Objectives The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents. Methods We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey. Results The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatme f choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, andmonotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategiesfor depressive episodes in adolescents were a combination of MS and an AAP, monotherapywith MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for thedepressive episodes in adolescents at high risk for bipolar disorder were a combination of MSand AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, andrisperidone were selected as first-line medications for the treatment of depressive episodes inadolescents with bipolar disorder. Conclusion It is expected that the present KMAP-BP 2022: children and adolescents will givethe direction and be usefully applied by clinicians to treat children and adolescents with bipolardisorders.

참고문헌 (35)

  1. Cox JH, "Clinical guidelines on long-term pharmacotherapy for bipolar disorder in children and adolescents", J Clin Med, 3, pp.135~143 (2014)
  2. National Collaborating Centre for Mental Health, "Bipolar disorder:the management of bipolar disorder in adults, children and adolescents, in primary and secondary care" (2006), British Psychological Society
  3. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
  4. 김대진, "주요 정신질환의 약물치료에 대한 한국형 알고리듬 개발 (2)- 한국형 알고리듬 개발 사업내용과 기본계획, 조직구성, 알고리듬 개발의 기본원칙, 개발방법, 제한점 및 사용 시 주의점 -", 대한정신약물학회지, 13(1), pp.30~36 (2002), 대한정신약물학회
  5. 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
  6. 신영철, "양극성 장애의 한국형 약물치료 알고리듬(II) : 조증 삽화", 대한정신약물학회지, 14(3), pp.223~230 (2003), 대한정신약물학회
  7. 민경준, "양극성 장애의 한국형 약물치료 알고리듬(III) : 우울 삽화", 대한정신약물학회지, 14(4), pp.336~346 (2003), 대한정신약물학회
  8. 전덕인, "양극성 장애의 한국형 약물치료 알고리듬(IV) : 급속 순환", 대한정신약물학회지, 15(1), pp.44~50 (2004), 대한정신약물학회
  9. 윤보현, "양극성 장애의 한국형 약물치료 알고리듬(V)：다른 치료 지침들과의 비교", 대한정신약물학회지, 15(2), pp.162~174 (2004), 대한정신약물학회
  10. 김찬형, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅰ)：전반적 평가", 대한정신약물학회지, 16(3), pp.225~233 (2005), 대한정신약물학회
  11. 신영철, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅱ)：약물의 선택", 대한정신약물학회지, 16(4), pp.285~291 (2005), 대한정신약물학회
  12. 전덕인, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅲ)：치료반응과 내약성", 대한정신약물학회지, 16(4), pp.292~300 (2005), 대한정신약물학회
  13. 민경준, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(IV) : 삶의 질", 대한정신약물학회지, 16(5), pp.396~405 (2005), 대한정신약물학회
  14. 전덕인, "한국형 양극성 장애 약물치료 알고리듬 2006(I)", 대한정신약물학회지, 17(4), pp.349~361 (2006), 대한정신약물학회
  15. Jon DI, "Revised Korean medication algorithm for bipolar disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
  16. Shin YC, "Korean medication algorithm for bipolar disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
  17. 심세훈, "한국형 양극성장애 약물치료 알고리듬 2014 : 소아 청소년", Mood and Emotion, 12(2), pp.67~78 (2014), 대한우울조울병학회
  18. Kowatch RA, "Treatment guidelines for children and adolescents with bipolar disorder", J Am Acad Child Adolesc Psychiatry, 44, pp.213~235 (2005)
  19. McClellan J, "Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder", J Am Acad Child Adolesc Psychiatry, 46, pp.107~125 (2007)
  20. Yatham LN, "Canadian Network for Mood and Anxiety Treatments (CANMAT)and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013", Bipolar Disord, 15, pp.1~44 (2013)
  21. Yatham LN, "Canadian Network for Mood and Anxiety Treatments (CANMAT)and International Society for Bipolar Disorders (ISBD) 2018guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
  22. "Guideline on clinical investigation of medicinal products in the treatment of depression" (2013)[URL]
  23. 심세훈, "한국형 양극성 장애 약물치료 알고리듬 2018 : 소아", 청소년, 2018, pp.16(3), 109~122[DOI]
  24. Sachs GS, "The expert consensus guideline series: medication treatment of bipolar disorder 2000", Postgrad Med, pp.1~104 (2000)[DOI]
  25. Geller B, "A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents", Arch Gen Psychiatry, 69, pp.515~528 (2012)
  26. Meduri M, "A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies", J Affect Disord, 191, pp.187~208 (2016)
  27. Suttajit S, "Quetiapine for acute bipolar depression : a systematic review and meta-analysis", Drug Des Devel Ther, 8, pp.827~838 (2014)
  28. Schneck CD, "A pharmacologic algorithm for youth who are at high risk for bipolar disorder", J Child Adolesc Psychopharmacol, 27, pp.796~805 (2017)
  29. Findling RL, "A double-blind and placebo-controlled trial of aripiprazole in symptomatic youths at genetic high risk for bipolar disorder", J Child Adolesc Psychopharmacol, 27, pp.864~874 (2017)
  30. Yee CS, "Maintenance pharmacological treatment of juvenile bipolar disorder : review and meta-analyses", Int J Neuropsychopharmacol, 22, pp.531~540 (2019)
  31. Shon SH, "Lamotrigine treatment of adolescents with unipolar and bipolar depression : a retrospective chart review", J Child Adolesc Psychopharmacol, 24, pp.285~287 (2014)
  32. Biederman J, "A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder", CNS Neurosci Ther, 16, pp.91~102 (2010)
  33. Hafeman DM, "Lithium versus other mood-stabilizing medications in a longitudinal study of youth diagnosed with bipolar disorder", J Am Acad Child Adolesc Psychiatry, 59, pp.1146~1155 (2020)
  34. Solmi M, "Safety of 80 antidepressants, antipsychotics, anti-attention-deficit", hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic metareview of 78 adverse effects, 2020, pp.19, 214~232
  35. Malhi GS, "The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders : bipolar disorder summary", Bipolar Disord, 22, pp.805~821 (2020)

관련 논문AI추천

Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary김문두, 박원명, 전덕인, 정명훈, 정종현, 추일한, Bo-Hyun Yoon, Chan-Mo Yang, Inki Sohn, Jeong Seok Seo, Jung Goo Lee, Se-Hoon Shim, Sung-Yong Park, Won Kim, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제4호Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision송후림, Bo-Hyun Yoon, Duk-In Jon, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Jung Goo Lee, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제4호한국형 양극성 장애 약물치료 알고리듬 2022: 총론김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호한국형 양극성 장애 약물치료 알고리듬 2022: 유지치료김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제3호한국형 양극성 장애 약물치료 알고리듬 2022: 조증 삽화김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호한국형 양극성 장애 약물치료 알고리듬 2022: 급속 순환형김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제3호

이 간행물의 다른 논문 (11건)

COVID-19 대규모 유행 국가에서 귀국한 격리자의 정신건강문제오은혜, 이정현, 전경선, 심민영, 하지현, 김우진, 김경애, 김창훈, 이다영, 현소연pp. 143-149의료보장형태와 수가체계에 따른 외래 정신질환 의료이용행태의 변화김명화, 김지우, 예례미, 이동윤pp. 150-155항정신병약물 치료에 부분적인 반응을 보인 조현병 환자에 대한 아미설프라이드 병용요법의 효과와 안전성에 관한 연구김현경, 김성곤, 허성영, 김연수pp. 156-161치매환자 가족조호자의 우울 및 불안과 연관요인홍수정, 성남주, 한명일, 최말례, 고요한pp. 162-169대학상담센터 서비스 신청서를 이용한 이용자 잠재계층 분류이상일, 이광로, 이선미, 이유경, 김명성, 정두영pp. 170-177
원문 보기